A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

Trial Profile

A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2016 Status changed from not yet recruiting to recruiting, according to a Spectrum pharmaceuticals media release.
    • 19 Jan 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
    • 23 Nov 2015 According to Spectrum media release, company has submitted an IND application to the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top